The latest insider transactions involving Helen Torley, President and CEO of Halozyme Therapeutics, Inc., indicate a significant divestment from company stock. Ms. Torley recently sold 50,000 shares of the common stock for an aggregate value estimated at $3.37 million. These sales took place within a short window, specifically between June 1 and June 3, 2026. The executed sale prices varied across this period, ranging from $66.314 to $69.692 per share.
It is notable that the underlying stock currently trades at $69.85. This represents a substantial increase of nearly 30% over the preceding year. Despite the upward movement in price, an analysis provided by InvestingPro suggests that the company may still be undervalued when measured against its calculated Fair Value.
Details of Stock Disposition and Trading Plans
These recent sales were directly linked to Ms. Torley's exercise of vested stock options. Through this mechanism, she acquired 50,000 shares of common stock at a cost of $12.07 per share, totaling $603,500 for the acquisition. Crucially, all these transactions were structured and executed under a pre-arranged trading agreement known as a Rule 10b5-1 plan. Ms. Torley established this specific trading plan on March 21, 2025.
The options that were exercised are part of an original grant dating back to February 22, 2017, and these vested rights are scheduled to expire in February 2027. Following the reported sales activity, Ms. Torley's direct holdings include 767,780 shares of Halozyme Therapeutics common stock. Furthermore, she retains an additional holding of 1,923 derivative shares structured as options to purchase common stock.
Financial Performance and Analyst Sentiment
Beyond the executive activity, Halozyme Therapeutics has provided positive financial updates. For the first quarter of 2026, the company reported robust results that managed to surpass consensus expectations set by Wall Street analysts. Specifically, Halozyme recorded an Earnings Per Share (EPS) of $1.60. This figure surpassed the projected estimate of $1.54. Additionally, the firm announced total revenue amounting to $377 million, which was higher than the forecasted benchmark of $358.45 million.
These financial outcomes translate into a considerable positive surprise for both earnings and revenue, registering 3.9% and 5.18% surprises, respectively. The company, whose overall valuation is assessed at $8.28 billion, maintains a